AIM ImmunoTech (AIMAW) Stock Price, News & Analysis

Company Overview

AIM ImmunoTech, Inc. is a clinical-stage biotechnology company specializing in immunotherapy and immunomodulation. The firm’s principal focus is the development and commercialization of rintatolimod, known commercially as Ampligen, a proprietary RNA-based therapeutic designed to modulate the innate immune response. The company leverages its deep scientific expertise in Toll-like receptor 3 (TLR3) activation to explore a broad range of indications including chronic fatigue syndrome, viral infections, oncology, and immuno-oncology combinations.

Ampligen’s mechanism of action as a TLR3 agonist has attracted interest from both government agencies and private partners. In the antiviral arena, AIM ImmunoTech has pursued development programs targeting HIV and other persistent viral pathogens, while also responding to emerging infectious disease threats. In oncology, the company is investigating Ampligen in combination with checkpoint inhibitors and other immune-oncology agents to enhance antitumor activity and improve patient outcomes across multiple cancer types.

Founded in 1981 as Hemispherx Biopharma and rebranded as AIM ImmunoTech in 2016, the company is headquartered in Miami, Florida, and conducts research, development, and manufacturing operations in the United States. Its clinical programs span North America, Europe and select regions in Asia, reflecting a strategic approach to global collaborations and regulatory interactions. AIM ImmunoTech maintains active partnerships with U.S. federal agencies, including the National Institute of Allergy and Infectious Diseases (NIAID) and the Department of Defense, to advance its therapeutic candidates through rigorous clinical evaluation.

The company’s leadership team is headed by Chairman Philip A. Frost, MD, whose extensive experience in pharmaceutical development complements the operational oversight of President and CEO Alessio Lombardi. Guided by a seasoned board of directors and scientific advisors, AIM ImmunoTech continues to expand its pipeline and seek regulatory milestones with the goal of delivering novel immunotherapeutics to patients facing unmet medical needs.

Key Stats

• Today's Range: $0.05 to $0.05
• 50-Day Range: $0.05 to $0.05
• 52-Week Range: $0.01 to $0.12
• Volume: 442 shs
• Average Volume: 32,382 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AIMAW Stock Analysis - Frequently Asked Questions

How have AIMAW shares performed this year?

AIM ImmunoTech's stock was trading at $0.0070 at the start of the year. Since then, AIMAW shares have increased by 542.9% and is now trading at $0.0450.

How do I buy shares of AIM ImmunoTech?

Shares of AIMAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Trading
• Current Symbol: OTCMKTS:AIMAW
• Previous Symbol: NASDAQ:AIMAW
• CIK: 1903464
• Web: www.aimimmunotech.com
• Phone: 646 722 2971
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A